VNRX has 36-month beta value of 1.07. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for VNRX is 76.15M, and currently, short sellers hold a 0.24% ratio of that float. The average trading volume of VNRX on June 13, 2025 was 238.83K shares.
VNRX) stock’s latest price update
VolitionRX Ltd (AMEX: VNRX)’s stock price has gone rise by 5.97 in comparison to its previous close of 0.56, however, the company has experienced a 3.29% increase in its stock price over the last five trading days. prnewswire.com reported 2025-06-12 that Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.
VNRX’s Market Performance
VolitionRX Ltd (VNRX) has seen a 3.29% rise in stock performance for the week, with a 27.40% gain in the past month and a 2.41% surge in the past quarter. The volatility ratio for the week is 2.66%, and the volatility levels for the past 30 days are at 4.87% for VNRX. The simple moving average for the past 20 days is 15.18% for VNRX’s stock, with a -1.41% simple moving average for the past 200 days.
Analysts’ Opinion of VNRX
Many brokerage firms have already submitted their reports for VNRX stocks, with H.C. Wainwright repeating the rating for VNRX by listing it as a “Buy.” The predicted price for VNRX in the upcoming period, according to H.C. Wainwright is $2.50 based on the research report published on April 08, 2025 of the current year 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VNRX, setting the target price at $7 in the report published on February 17th of the previous year.
VNRX Trading at 18.25% from the 50-Day Moving Average
After a stumble in the market that brought VNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.78% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNRX starting from Innes Guy Archibald, who purchase 20,000 shares at the price of $0.54 back on Jun 03 ’25. After this action, Innes Guy Archibald now owns 888,689 shares of VolitionRX Ltd, valued at $10,772 using the latest closing price.
Micallef Jacob Vincent, the Chief Scientific Officer of VolitionRX Ltd, purchase 50,000 shares at $0.43 during a trade that took place back on May 19 ’25, which means that Micallef Jacob Vincent is holding 426,033 shares at $21,500 based on the most recent closing price.
Stock Fundamentals for VNRX
Current profitability levels for the company are sitting at:
- -14.25 for the present operating margin
- 0.32 for the gross margin
The net margin for VolitionRX Ltd stands at -18.36. The total capital return value is set at -75.48.
Based on VolitionRX Ltd (VNRX), the company’s capital structure generated -0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -11.9. The debt to equity ratio resting at -0.09. The interest coverage ratio of the stock is -111.98.
Currently, EBITDA for the company is -25.62 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 46.35. The receivables turnover for the company is 6.97for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.40.
Conclusion
To put it simply, VolitionRX Ltd (VNRX) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
